Iberogas (Bitter Candytuft Fresh Plant Extract, Matricaria Liquid Extract, Menthae Piperitae Folium, Melissae)

Bitter candytuft extract contains bioactive flavonoids and essential oils that can exert mild antispasmodic and carminative actions. These compounds may interact with smooth‑muscle receptors and modulate local inflammatory pathways, providing gentle supportive effects on the gastrointestinal tract and upper respiratory mucosa.

The appropriate dose of Iberogas is determined by the prescribing healthcare professional based on individual needs and product labeling. Patients should follow the dosage instructions provided by their clinician or the product’s package insert.

Safety data for Iberogas in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider before using the product to assess potential risks and benefits.

To order Iberogas, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Iberogas combines bitter candytuft, matricaria, peppermint leaf and melissa extracts, offering a broader spectrum of phytochemicals than many single‑herb products. While other supplements may focus on one botanical, Iberogas provides a multi‑herb blend that may address several mild, traditional wellness concerns, though direct clinical comparisons are not established.

Store Iberogas at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the seal remains intact until use.

Iberogas is taken orally as directed by a healthcare professional. The product is typically consumed with water, and the exact administration method (e.g., with or without food) should follow the prescribing clinician’s guidance.

The most serious risks include rare but severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, and potential hepatic injury. Users should seek immediate medical attention if they experience symptoms like difficulty breathing, widespread rash, jaundice, or unexplained fatigue.

Individuals with known hypersensitivity to any of the listed botanical ingredients, those taking anticoagulants or MAO inhibitors without medical supervision, and patients with severe liver or kidney disease should avoid using Iberogas unless advised otherwise by a qualified healthcare professional.